Limitations of presently available glycopeptides in the treatment of Gram-positive infection
Authors:
- R.G. FinchRFR.G. Finch
- 1 January 2001
- journal article
- review article
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 7 (4) , 53-65
Abstract
No abstract availableKeywords
This publication has 133 references indexed in Scilit:
- Management of Serious Staphylococcal Infections in the Outpatient SettingDrugs, 1997
- Comparative Study of Teicoplanin vs Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus BacteraemiaClinical Drug Investigation, 1996
- Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1995
- Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patientsIntensive Care Medicine, 1994
- TeicoplaninDrugs, 1994
- Efficacy and pharmacokinetics of teicoplanin in hemodialysis patientsInfection, 1993
- Evaluation of the teicoplanin broth microdilution and disk diffusion susceptibility tests and recommended interpretive criteriaDiagnostic Microbiology and Infectious Disease, 1992
- TeicoplaninDrugs, 1990
- Emergence of Vancomycin Resistance in Coagulase-Negative StaphylococciNew England Journal of Medicine, 1987
- Relapse of Pseudomembranous Colitis after Vancomycin TherapyNew England Journal of Medicine, 1979